局限性前列腺癌主动监测、根治性前列腺切除术与外照射放疗的成本效果:ProtecT试验分析
基于ProtecT试验6年生活质量和10年肿瘤学数据构建Markov模型,比较主动监测、根治性前列腺切除术和外照射放疗的成本效果。随机化后6年,主动监测人均成本最低(12143美元),根治性前列腺切除术和外照射放疗相对主动监测的增量成本效果比分别为127752美元/QALY和381894美元/QALY。随机化后10年,根治性前列腺切除术(5627美元/QALY)和外照射放疗(78291美元/QALY)比主动监测更具成本效果。
要点
- 随机化后6年人均成本:主动监测12143美元、根治性前列腺切除术17781美元、外照射放疗29238美元。
- 6年时相对主动监测的增量成本效果比:根治性前列腺切除术127752美元/QALY,外照射放疗381894美元/QALY。
- 10年时根治性前列腺切除术(5627美元/QALY)和外照射放疗(78291美元/QALY)比主动监测更具成本效果。
核心结论
- 主动监测在诊断后最初数年是管理局限性前列腺癌具有成本效果的策略,但随着随访延长治疗的相对成本效果显现。
研究设计与样本
- 基于ProtecT试验结局的Markov模型成本效果分析,比较主动监测、根治性前列腺切除术和外照射放疗,使用6年生活质量数据和10年肿瘤学数据,成本基于2017年Medicare报销,效用值取自文献,并进行单变量和多变量敏感性分析。
主要发现
- 随机化后6年人均成本:主动监测12143美元,根治性前列腺切除术17781美元,外照射放疗29238美元。
- 相对主动监测的增量成本效果比:根治性前列腺切除术127752美元/QALY,外照射放疗381894美元/QALY。
- 随机化后10年,根治性前列腺切除术(5627美元/QALY)和外照射放疗(78291美元/QALY)比主动监测更具成本效果。
- 模型对主动监测的转移率敏感,10年转移率阈值为2.4%,低于该阈值时主动监测比根治性前列腺切除术更具成本效果。
- 10年多变量敏感性分析采用100000美元/QALY的支付意愿阈值时,最具成本效果的策略在45%的模型微观模拟中为根治性前列腺切除术、30%为外照射放疗、25%为主动监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite increasing emphasis on value based care, to our knowledge the cost-effectiveness of prostate cancer management options has not been compared using prospective clinical trial data. The ProtecT (Prostate Testing for Cancer and Treatment) trial demonstrated no difference in survival in patients randomized to active surveillance, external beam radiotherapy or radical prostatectomy. We compared cost-effectiveness among the arms of ProtecT. MATERIALS AND METHODS: Using a Markov model we compared the cost-effectiveness of active surveillance, radical prostatectomy and external beam radiotherapy based on ProtecT outcomes, specifically 6-year quality of life data and 10-year oncologic data. Costs were based on 2017 Medicare reimbursement while utility values were assigned using the literature. Univariable and multivariable sensitivity analyses were performed. RESULTS: Six years after randomization the mean costs per patient were $12,143 for active surveillance, $17,781 for radical prostatectomy and $29,238 for external beam radiotherapy. The incremental cost-effectiveness ratio relative to active surveillance was $127,752/QALY for radical prostatectomy and $381,894/QALY for external beam radiotherapy. Ten years after randomization radical prostatectomy ($5,627/QALY) and external beam radiotherapy ($78,291/QALY) were more cost-effective than active surveillance. The model was sensitive to the metastasis rate on active surveillance with a threshold of 2.4% at 10 years, below which active surveillance was more cost-effective than radical prostatectomy. On multivariable sensitivity analysis at 10 years using a willingness to pay threshold of $100,000/QALY the most cost-effective strategy was radical prostatectomy in 45% of model microsimulations, external beam radiotherapy in 30% and active surveillance in 25%. CONCLUSIONS: Although active surveillance represents a cost-effective strategy to manage localized prostate cancer during the initial several years after diagnosis, the relative cost-effectiveness of treatment emerges with extended followup.
引用
- Sharma V, Wymer KM, Borah BJ, et al. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial. J Urol. 2019. PMID: 31112105. doi:10.1097/JU.0000000000000345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。